Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 28,650 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $80.01, for a total value of $2,292,286.50. Following the transaction, the chief executive officer now directly owns 258,650 shares of the company’s stock, valued at $20,694,586.50. The sale was disclosed in a filing with the SEC, which is available at this link.

Spark Therapeutics, Inc. (ONCE) traded up 0.14% during trading on Friday, reaching $76.96. The company had a trading volume of 2,518,809 shares. The firm’s market capitalization is $2.38 billion. Spark Therapeutics, Inc. has a 52-week low of $35.07 and a 52-week high of $78.08. The company has a 50-day moving average of $63.15 and a 200-day moving average of $58.70.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 55.25%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter in the prior year, the firm earned ($1.04) earnings per share. The company’s revenue was up 14.7% on a year-over-year basis. Analysts expect that Spark Therapeutics, Inc. will post ($6.80) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (ONCE) CEO Jeffrey D. Marrazzo Sells 28,650 Shares” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/04/spark-therapeutics-inc-once-ceo-jeffrey-d-marrazzo-sells-28650-shares.html.

Several institutional investors have recently bought and sold shares of ONCE. Russell Investments Group Ltd. bought a new position in Spark Therapeutics during the fourth quarter valued at approximately $883,000. State Board of Administration of Florida Retirement System boosted its position in Spark Therapeutics by 4.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 8,204 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 320 shares in the last quarter. Norges Bank bought a new position in Spark Therapeutics during the fourth quarter valued at approximately $8,232,000. UBS Asset Management Americas Inc. boosted its position in Spark Therapeutics by 6.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 185,036 shares of the biotechnology company’s stock valued at $9,233,000 after buying an additional 10,616 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 4,875 shares in the last quarter. Institutional investors and hedge funds own 88.96% of the company’s stock.

A number of equities analysts have recently issued reports on the company. Stifel Nicolaus reissued a “buy” rating and set a $92.00 target price (up from $77.00) on shares of Spark Therapeutics in a research note on Thursday. Cowen and Company reissued an “outperform” rating and set a $95.00 target price (up from $75.00) on shares of Spark Therapeutics in a research note on Thursday. Jefferies Group LLC reissued a “buy” rating and set a $95.00 target price (up from $85.00) on shares of Spark Therapeutics in a research note on Thursday. BMO Capital Markets reissued an “outperform” rating on shares of Spark Therapeutics in a research note on Thursday. Finally, UBS AG reissued a “buy” rating and set a $92.00 target price (up from $70.00) on shares of Spark Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $82.27.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.